Monday, October 26, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· December 30, 2025

Ellomay Capital Reports Results for the Three and Nine Months Ended September 30, 2025

View original at globenewswire.com
Ellomay Capital Reports Results for the Three and Nine Months Ended September 30, 2025 TEL-AVIV, Israel, Dec. 30, 2025 (GLOBE NEWSWIRE) -- TEL-AVIV, Israel, Dec…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • 210 MW of Italian development pipeline reached 'Ready to Build' status with construction scheduled to begin Q4 2026

    80% confidence

  • Regulatory changes and tariff uncertainty limit forecasting beyond current USA plans

    80% confidence

  • Green certificate sales agreements of ~€1/certificate expected to result in significant profitability increase when Netherlands blending obligation starts

    80% confidence

  • Spain needs significant battery storage capacity increase to address grid stability concerns from excess renewable energy

    80% confidence

  • Construction of 160 MW Italian solar project expected to complete by end of 2026

    80% confidence

  • USD exchange rate decline on Dorad deposits creates natural hedge against future USD expenses for gas purchases, O&M, and Dorad 2 construction

    80% confidence

  • Compensation expected from EPC contractor for construction delays in USA projects

    80% confidence

  • Netherlands biogas expansion target capacity of ~24M m³/year gas represents +50% increase from current ~16M m³/year

    80% confidence

  • Dorad 2 project target financial closing date is June 30, 2026

    80% confidence

  • Ellomay Solar license for 28 MWp + 2 hours battery storage expected in coming months

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com